Experimental animal models for anaerobic infections.

An experimental animal model that stimulates the mixed aerobic-anaerobic microflora of intraabdominal sepsis was used to study antimicrobial efficacy in vivo. Treatment of infected rats with chloramphenicol resulted in only a modest reduction in the percentage of animals surviving infection with abscesses at necropsy. This unanticipated observation led to further exploration of the predominant anaerobes associated with the experimental infection. In vitro cultures of Bacteroides fragilis, susceptible to chloramphenicol in traditional tests, were capable of reducing chloramphenicol to its aryl amine derivative, which is biologically inactive. In contrast, metronidazole, an antimicrobial agent active against anaerobes, reduced the coli-metronidazole, an antimicrobial agent active against anaerobes, reduced the coli-form-associated mortality in this animal model. Subsequent studies showed that this reduction in mortality is dependent on the presence of an anaerobe and that the levels of Escherichia coli in mixed continuous culture with B. fragilis are reduced by addition of metronidazole. This reduction following addition of metronidazole was not observed either in a pure culture of E. coli or when clindamycin was added to a mixed culture. In a modification of the previously described model, infective material was placed subcutaneously into Wistar rats. Studies with this model suggested that the host's response to bacterial challenge is dependent on the site of infection and that organotropism of the implanted bacterial species is an important determinant of infection.

[1]  D. Kasper,et al.  Immunochemical and biologic studies of the lipopolysaccharide of Bacteroides melaninogenicus subspecies asaccharolyticus. , 1978, Journal of immunology.

[2]  J. Bartlett,et al.  Quantitative determination of the antibody response to the capsular polysaccharide of Bacteroides fragilis in an animal model of intraabdominal abscess formation. , 1977, The Journal of infectious diseases.

[3]  B. Polk,et al.  Isolation and identification of encapsulated strains of Bacteroides fragilis. , 1977, The Journal of infectious diseases.

[4]  J. Bartlett,et al.  The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. , 1977, The Journal of infectious diseases.

[5]  Miklós Müller,et al.  Antitrichomonad Action, Mutagenicity, and Reduction of Metronidazole and Other Nitroimidazoles , 1976, Antimicrobial Agents and Chemotherapy.

[6]  J. Bartlett,et al.  Rapid Microbiological Assay for Chloramphenicol and Tetracyclines , 1976, Antimicrobial Agents and Chemotherapy.

[7]  John L. Johnson,et al.  Reinstatement of Species Rank for Bacteroides fragilis, B. ovatus, B. distasonis, B. thetaiotaomicron, and B. vulgatus: Designation of Neotype Strains for Bacteroides fragilis (Veillon and Zuber) Castellani and Chalmers and Bacteroides thetaiotaomicron (Distaso) Castellani and Chalmers , 1976 .

[8]  S. Gorbach,et al.  Effect of dissolved oxygen and Eh and Bacteroides fragilis during continuous culture , 1976, Applied and environmental microbiology.

[9]  J. Bartlett,et al.  Microbial synergy in experimental intra-abdominal abscess , 1976, Infection and immunity.

[10]  D. Kasper,et al.  Immunochemical characterization of the outer membrane complex of Bacteroides fragilis subspecies fragilis. , 1975, The Journal of infectious diseases.

[11]  J. Bartlett,et al.  Antimicrobial therapy of experimental intraabdominal sepsis. , 1975, The Journal of infectious diseases.

[12]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[13]  J. Bartlett,et al.  Experimental Intra-Abdominal Abscesses in Rats: Development of an Experimental Model , 1974, Infection and immunity.

[14]  J. Bartlett,et al.  Experimental Intra-Abdominal Abscesses in Rats: Quantitative Bacteriology of Infected Animals , 1974, Infection and immunity.

[15]  M. P. Bryant,et al.  Nutritional features of Bacteroides fragilis subsp. fragilis. , 1974, Applied microbiology.

[16]  J. Bartlett,et al.  Anaerobic Infections. , 1974, American family physician.

[17]  J. Bartlett,et al.  Anaerobic infections (second of three parts). , 1974, The New England journal of medicine.

[18]  J. Bartlett,et al.  Anaerobic infections. 1. , 1974, The New England journal of medicine.

[19]  H. Maibach,et al.  Protection of Chicken Embryos by Viridans Streptococci Against the Lethal Effect of Staphylococcus aureus , 1974, Infection and immunity.

[20]  G. Hill,et al.  Liver Abscess Production by Non-Spore-Forming Anaerobic Bacteria in a Mouse Model , 1974, Infection and immunity.

[21]  S. Miyamura,et al.  [Inactivation of chemotherapeutic agents by clostridia]. , 1969, Nihon saikingaku zasshi. Japanese journal of bacteriology.

[22]  F. Meleney BACTERIAL SYNERGISM IN DISEASE PROCESSES: WITH A CONFIRMATION OF THE SYNERGISTIC BACTERIAL ETIOLOGY OF A CERTAIN TYPE OF PROGRESSIVE GANGRENE OF THE ABDORMINAL WALL , 1931, Annals of surgery.

[23]  Lillian V. Holdeman,et al.  Anaerobe Laboratory manual , 1977 .

[24]  M. Locke,et al.  Synergism in experimental infections with non-sporulating anaerobic bacteria. , 1949, The Journal of infectious diseases.